Mylan Cuts List Price by More Than 50% for Generic Copaxone
July 9, 2018 – Manufacturer Mylan has reduced the list price for its generic to Teva’s Copaxone® (glatiramer acetate injection) by more than half. Previously listed at $5,000 per month, the drug now has a list price of just $1,900 per month.
Teva currently offers brand name Copaxone at a list price of $5,800 month, and has an available $0 copay program for qualified patients. Mylan has its own $0 copay program, and has not announced a reason for the price reduction of its generic product, which is available in both 40mg/mL and 20mg/mL strengths. Sandoz also currently offers a Copaxone generic, sold under the name Glatopa® on the U.S. market. Their product is available in both 20mg/mL and 40mg/mL dosage strengths.
Indicated to treat relapsing forms of multiple sclerosis, glatiramer acetate injection can be self-administered, and is taken either once daily (20mg/mL) or three times per week (40mg/mL).
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.